https://european-biotechnology.com/wp-content/uploads/2024/04/money-Nattanan_Kanchanaprat.jpg12811920Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-11-21 05:20:002019-11-21 05:20:00GHO capital launches EU’s largest fund ever for life sciences
Thicker than ever: The 21st edition of the Guide to German Biotech Companies has been published. Almost 120 companies from the vibrant biotech sector present themselves in the English-language yearbook.
Danish Novo Nordisk A/S has secured access to Dicerna Inc’s GalXC RNAi technology in a R&D deal worth US$225m upfront over three years comprising 30 liver targets.
The EU has made poor progress combatting antimicrobial resistance, a report from the European Court of Auditors (ECA) warns. Innovators need to be supported, urges the BEAM Alliance.
Researchers at French-US allogeneic CAR-T cell developer Cellectis SA have designed an engineered CAR-T cell that secretes IL-12 upon contact with tumour cells.
https://european-biotechnology.com/wp-content/uploads/2024/04/Cellectis.jpg310608Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-11-15 06:58:442019-11-15 06:58:44Cellectis presents way to safer CAR-Ts
Swiss Lonza announced that CEO Marc Funk is leaving the company. Chairman Albert Baehny will take over as CEO on an ad interim basis until a successor is found.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2019-11-13 07:50:002019-11-13 07:50:00Lonza chair Albert Baehny takes over as interim CEO
https://european-biotechnology.com/wp-content/uploads/2024/04/20191112-ai.jpg6751200Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2019-11-12 08:19:002019-11-12 08:19:00Vaximm goes East for cancer vaccine deal
GHO capital launches EU’s largest fund ever for life sciences
Latest NewsGHO Capital raises €975m in largest ever European private equity healthcare fund.
Update: BIO-Europe growing further
Latest NewsEurope’s largest partnering event, the BIO-Europe, hit another visitor record on the occasion of its 25th anniversary in Hamburg.
Zelluna Immunotherapy and Glycostem Therapeutics in licence deal
Latest NewsZelluna Immunotherapy and Glycostem Therapeutics have partnered to develop allogeneic TCR-NK therapies.
Growing sector – growing guide
ProductsThicker than ever: The 21st edition of the Guide to German Biotech Companies has been published. Almost 120 companies from the vibrant biotech sector present themselves in the English-language yearbook.
Novo secures Dicerna’s RNAi liver assets
Latest NewsDanish Novo Nordisk A/S has secured access to Dicerna Inc’s GalXC RNAi technology in a R&D deal worth US$225m upfront over three years comprising 30 liver targets.
EU with poor success in fighting superbugs
Latest NewsThe EU has made poor progress combatting antimicrobial resistance, a report from the European Court of Auditors (ECA) warns. Innovators need to be supported, urges the BEAM Alliance.
Cellectis presents way to safer CAR-Ts
Latest NewsResearchers at French-US allogeneic CAR-T cell developer Cellectis SA have designed an engineered CAR-T cell that secretes IL-12 upon contact with tumour cells.
Magenta Therapeutics exercises ATAC licence option
Latest NewsMagenta Therapeutics has exercised the option to licence Heidelberg Pharma AG’s anti-CD45-Antibody Targeted Amanitin Conjugate (ATAC).
Lonza chair Albert Baehny takes over as interim CEO
AppointmentsSwiss Lonza announced that CEO Marc Funk is leaving the company. Chairman Albert Baehny will take over as CEO on an ad interim basis until a successor is found.
Vaximm goes East for cancer vaccine deal
Latest NewsSwiss-German biotech Vaximm is teaming up with Tokyo-based AI specialist NEC to advance personalised neoantigen cancer vaccines.